# Arcutis Biotherapeutics, Inc. Common Stock (ARQT)

> Arcutis Biotherapeutics, Inc. Common Stock (ARQT) trades at $26.82 (-21.20%) as of 2:43:32 PM EST on Nov 5, 2026, +10.88% over the past month. Market cap is $4.28B, with 9.8 days to cover in short interest.

Canonical: https://massive.com/quote/arqt
Data as of: 2026-11-05T19:43:32.188Z (15-minute delayed)
Source: Massive (https://massive.com/docs/llms.txt)

## Price

**$26.82** -7.23 (-21.20%)
As of 2:43:32 PM EST on Nov 5, 2026 · 15-minute delayed
Nasdaq · usd

## Stock performance

How Arcutis Biotherapeutics, Inc. Common Stock (ARQT) stock has performed from one day to one year, with its 52-week range.

| Period | Return |
| --- | --- |
| 1D | -21.29% |
| 1W | -16.17% |
| 1M | +10.88% |
| YTD | -7.71% |
| 1Y | +6.77% |
| 52-wk range | $19.30 – $34.80 |

From daily closes through Nov 5, 2026.

## Key statistics

Today's trading snapshot for ARQT: day range, open, previous close, volume and market cap.

| Measure | Value |
| --- | --- |
| Day range | $25.78 – $29.49 |
| Open | $29.00 |
| Prev close | $34.05 |
| Volume | 4.83M |
| Market cap | $4.28B |
| Shares out | 125.69M |

## Valuation and profitability ratios

Valuation and profitability ratios for Arcutis Biotherapeutics, Inc. Common Stock: P/E, P/S, P/B, ROE and more.

| Measure | Value |
| --- | --- |
| P/E | 150.07 |
| P/S | 9.22 |
| P/B | 19.40 |
| P/FCF | 109.32 |
| ROE | 12.9% |
| ROA | 5.8% |
| Debt/Equity | 0.49 |
| Div yield | 0.00% |

As of Nov 4, 2026

## Insider trading

[Arcutis Biotherapeutics, Inc. Common Stock (ARQT) insider trading](https://massive.com/quote/arqt/insider-trading.md): open-market Form 4 buys and sells by Arcutis Biotherapeutics, Inc. Common Stock insiders over the last 12 months.

## 8-K filings

Material corporate events Arcutis Biotherapeutics, Inc. Common Stock has disclosed to the SEC on Form 8-K.

- Nov 4, 2026 · [Quarterly earnings](https://massive.com/quote/sec-filings/8-k/earnings-releases.md)
  “On November 4, 2026, Arcutis Biotherapeutics, Inc. issued a press release relating to its financial results for the quarter ended September 30, 2026.”
- Oct 28, 2026 · Director appointment
  “On October 23, 2026, the Board of Directors (the "Board") of Arcutis Biotherapeutics, Inc. (the "Company") increased the authorized number of directors on the Board from ten to eleven directors and appointed Dr. Robert Scott as a new member of the Board and the Nominating and Corporate Governance Committee of the Board. Dr. Scott was appointed as a Class II director, with a term expiring at the Company's 2028 annual meeting of stockholders.”
- Aug 5, 2026 · Executive officer appointment
  “The Company has appointed Robert Lisicki as interim executive vice president, starting August 17, 2026, and as interim chief commercial officer, effective upon Mr. Edwards' departure from the Company on August 21, 2026.”
- Jul 16, 2026 · Executive compensation change
  “As a non-employee director, Mr. Peetz will receive compensation in accordance with the Company's non-employee director compensation program, as amended. Pursuant to this program, upon the effective date of his appointment to the Board, Mr. Peetz received an initial stock option award exercisable for 21,486 shares of the Company's common stock, and is eligible for the prorated annual equity award fair valued at approximately $350,000 (allocated 65% to stock options and 35% to restricted stock units) and for the prorated portion of the annual cash retainer in the amount of $50,000 for service on the Board.”
- Jun 9, 2026 · Annual meeting results
  “On June 5, 2026, Arcutis Biotherapeutics, Inc. (the "Company") held its 2026 Annual Meeting of Stockholders (the "Annual Meeting"). At the Annual Meeting, the Company's stockholders voted on three proposals... All matters voted on at the Annual Meeting were approved.”

## ARQT short interest

How heavily ARQT is shorted: shares short, days to cover and average daily volume.

| Measure | Value |
| --- | --- |
| Days to cover | 9.8 |
| Short interest | 20.49M |
| Avg volume | 2.1M |

As of Oct 15, 2026 · reported to FINRA twice monthly.

## ARQT news

The latest news and headlines about Arcutis Biotherapeutics, Inc. Common Stock (ARQT).

- [Sarepta Therapeutics (SRPT) Earnings Expected to Grow: Should You Buy?](https://www.zacks.com/stock/news/3018559/sarepta-therapeutics-srpt-earnings-expected-to-grow-should-you-buy?cid=CS-ZC-FT-fundamental_analysis|yseop_template_9-3018559) · Zacks Investment Research · Oct 29, 2026 · negative sentiment
- [Arcutis Biotherapeutics, Inc. (ARQT) Reports Next Week: Wall Street Expects Earnings Growth](https://www.zacks.com/stock/news/3017164/arcutis-biotherapeutics-inc-arqt-reports-next-week-wall-street-expects-earnings-growth?cid=CS-ZC-FT-fundamental_analysis|yseop_template_9-3017164) · Zacks Investment Research · Oct 28, 2026 · positive sentiment
- [Arcutis Appoints Rob Scott, MD to Board of Directors](https://www.globenewswire.com/news-release/2026/10/28/3390222/0/en/arcutis-appoints-rob-scott-md-to-board-of-directors.html) · GlobeNewswire Inc. · Oct 28, 2026 · positive sentiment
- [Arcutis to Report Third Quarter 2026 Financial Results and Host Conference Call on November 4, 2026](https://www.globenewswire.com/news-release/2026/10/21/3385871/0/en/arcutis-to-report-third-quarter-2026-financial-results-and-host-conference-call-on-november-4-2026.html) · GlobeNewswire Inc. · Oct 21, 2026 · positive sentiment
- [Arcutis Presents ZORYVE® (roflumilast) Data and Real-World Topical Corticosteroid Research at EADV and Fall Clinical](https://www.globenewswire.com/news-release/2026/10/09/3378045/0/en/arcutis-presents-zoryve-roflumilast-data-and-real-world-topical-corticosteroid-research-at-eadv-and-fall-clinical.html) · GlobeNewswire Inc. · Oct 9, 2026 · positive sentiment

## About Arcutis Biotherapeutics, Inc. Common Stock

Arcutis Biotherapeutics Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Its current portfolio is comprised of differentiated topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population. The Company has one reportable segment relating to the development and commercialization of treatments for dermatological diseases.

| Measure | Value |
| --- | --- |
| Exchange | Nasdaq |
| Market | stocks |
| Type | CS |
| Currency | USD |
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 354 |
| Listed | Jan 31, 2020 |

[Company website](https://www.arcutis.com)

## FAQ

### What is the Arcutis Biotherapeutics, Inc. Common Stock (ARQT) stock price today?

Arcutis Biotherapeutics, Inc. Common Stock (ARQT) is trading at $26.82 (-21.20% on the day) as of 2:43:32 PM EST on Nov 5, 2026. Prices are delayed at least 15 minutes; real-time quotes are available from the Massive API.

### What is Arcutis Biotherapeutics, Inc. Common Stock?

Arcutis Biotherapeutics Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs.

### What is the short interest in ARQT?

As of Oct 15, 2026, ARQT has 20.49M shares short and 9.8 days to cover.

### What exchange is ARQT listed on?

Arcutis Biotherapeutics, Inc. Common Stock (ARQT) trades on Nasdaq in USD, in the PHARMACEUTICAL PREPARATIONS industry.

## Live data

Prices here are 15-minute delayed. For real-time ARQT quotes and the full history behind this page, use the Massive API or MCP server:

- `GET https://api.massive.com/v3/snapshot?ticker.any_of=ARQT`

Requests need a Massive API key. API reference for agents: https://massive.com/docs/llms.txt. Connect an AI agent through the Massive MCP server: https://massive.com/docs/ai-tools.

## Related

- [Arcutis Biotherapeutics, Inc. Common Stock (ARQT) insider trading](https://massive.com/quote/arqt/insider-trading.md)
- [SEC 8-K events](https://massive.com/quote/sec-filings/8-k.md)
- [Markets overview](https://massive.com/quote/index.md)

Nothing here is investment advice. Data and content are provided for informational purposes under the Massive Terms of Service: https://massive.com/terms